Management of bronchiolitis
Management of acute bronchiolitis is largely supportive. [1] There is currently no proven effective therapy other than oxygen for hypoxic children (Table 1) . [2, 3] The following supportive treatments have been used for the management of bronchiolitis:
• humidified oxygen • inhaled short-acting bronchodilator therapy • nebulised hypertonic saline (3% or 5%) • corticosteroids: oral or nebulised • inhospital use of antiviral treatments, e.g. ribavirin in ventilated children • montelukast • antibiotics.
Humidified low-flow oxygen (0.5 -3.0 L/min) applied by nasal prongs is effective for hypoxic children. Nasal prongs give a maximum inspired oxygen of 28 -35% except in small infants, when higher oxygen concentrations may be obtained. Headbox oxygen is an alternative and is well tolerated by young infants. It requires no humidification, but high flow and a mixing device are needed to ensure that the correct oxygen concentration is delivered. However, there is wastage of oxygen and the delivered oxygen concentration (FiO 2 ) is unpredictable. Facemask oxygen delivers between 28% and 65% oxygen at a flow rate of 6 -10 L/min. In severely hypoxic infants who are not ventilated, oxygen should be administered using a polymask, which enables FiO 2 concentrations of 60 -80% being achieved. Oxygen should be weaned when the child improves clinically and as hypoxia resolves.
Rapid, short-acting inhaled bronchodilator therapy such as albuterol or salbutamol has not shown any important clinical benefits in the treatment of bronchiolitis. [1, 4] A Cochrane review (30 trials, 1 992 infants, including inpatient and emergency settings) reported no effects [4] Given the potential for adverse side-effects and the cost of these treatments, bronchodilators should not be recommended for the routine management of bronchiolitis. For studies of adrenaline compared with placebo, a Cochrane review (19 studies, 2 256 children) suggested a short-term benefit from adrenaline, especially in the first 24 hours of the illness. [5] No differences were found for length of hospital stay, but there was some evidence that adrenaline was effective for reducing the number of hospital admissions. [5] One large, high-quality trial suggested that combined treatment with dexamethasone and adrenaline may significantly reduce the number of admissions. [5] However, there is currently insufficient evidence to support the use of adrenaline for the treatment of bronchiolitis among children admitted to hospital. Inhaled ipratropium bromide is an ineffective treat ment. [6] Conflicting data have been reported for the efficacy of hypertonic saline nebulisation administered as nebulised 3% or 5% saline for acute bronchiolitis. A 2013 Cochrane review (11 trials, 1 090 children) reported a reduction in duration of hospital stay and improvement in clinical scores in children who were inpatients, but no short-term effects in children in four trials done in an emergency unit setting. [7] However, recently the largest reported randomised controlled study of nebulised hypertonic saline in acute bronchiolitis: randomised controlled trial and economic evaluation (SABRE) in hypoxic children, found no difference in outcomes between children who received hypertonic saline compared with those who received standard care. [8] Other recently published randomised trials have also added to the evidence against the use of hypertonic saline in bronchiolitis, showing no difference in length of hospital stay, clinical scores or improvement in oxygenation compared with children receiving normal saline nebulisation or salbutamol. [9] [10] [11] [12] The current evidence does not demonstrate consistent benefit with the use of hypertonic saline; currently, this strategy should therefore not be recommended.
Systemic or inhaled corticosteroids have been shown not to be effective in reducing hospital admission or improving clinical scores in ambulatory patients. [1, 13] However, among inpatients, cortico steroids improved clinical scores within the first 12 hours, but did not have any effect on length of stay. Therefore, corticosteroids should not be routinely recommended. [13] Five randomised controlled trials have shown no evidence of benefit for inhaled corticosteroids started in the acute phase of bronchiolitis for prevention of post-bronchiolitic wheezing. [14] Routine use of syste mic or inhaled steroids in the management of bronchiolitis is therefore not indicated.
Montelukast has no effect on the clinical course or outcome of bronchiolitis. A study of montelukast (4 mg daily until discharge) found that it demonstrated no improvement in the clinical course of the disease. [15] In a study of post-bronchiolitis wheeze, montelukast did not improve respiratory symptoms of post-RSV bronchiolitis in children. [16] Similarly, aerosolised ribavirin has been reported not to have any significant consistent beneficial effect in the management of bronchiolitis. [1, 17] The use of chest physiotherapy has been shown not to change the course of bron chiolitis or its outcome. Chest physiotherapy using vibration and percussion techniques does not reduce the length of hospital stay or oxygen requirements or improve the severity clinical scores in infants with acute bronchiolitis. [18] Finally, a Cochrane review of antibiotics compared with placebo for bronchiolitis, including two studies of azithromycin com pared with placebo, found no difference in length of hospital stay, duration of oxygen administration or readmission rates. [19] Antibiotics should therefore not be used routinely in bronchiolitis, except in children with severe disease in whom bacterial lower respiratory tract infection is suspected.
Prevention of RSV disease in high-risk children
The specific RSV monoclonal antibody, palivizumab, is available for children at risk of severe bronchiolitis.
With regard to RSV-associated morbidity, the risk of hospitalisation is 5.2/1 000 (4.8 -5.7) cases. [20] However, this risk rapidly increases with decreasing gestational age, being 19.3/1 000 in premature infants <29 weeks of gestational age and with congenital heart defects. RSV hospitalisation rates are highest at 120.8/1 000 in the first 6 months after delivery, declining to 63.2/1 000 at 6 -12 months of age and to 18.2/1 000 in the >12-month age group. [20] Similarly, the risk of hospitalisation in children with chronic lung disease of prematurity is 562.5/1 000 in the <6-month age group, 214.3/1 000 in the 6 -12-month age group, and 73.4/1 000 in those >12 months of age. [20] Palivizumab has been demonstrated to be effective in reducing RSV-related hospi talisation and the need for intensive care unit (ICU) admission among all premature infants and those with bronchopulmonary dysplasia by 55%, with an adjusted risk reduction of 3 -9% in a Level 1 study. [21] Meta-analysis has confirmed this across all populations of preterm infants. [22] This monoclonal antibody has also been shown to reduce duration of hospitalisation stay and need for oxygen in young children with congenital heart defects. [23] Given the current burden of RSV disease, it is estimated that the number needed to treat to prevent one hospitalisation from RSV disease in premature infants and children with chronic lung disease or congenital heart defects is between 16 and 23, which increases sixfold for the prevention of ICU admission or death. At the current cost of palivizumab, it is extre mely expensive to recommend its widespread use; it is therefore restricted to high-risk groups. [24] For the prevention of RSV-associated bronchiolitis, the South African (SA) guide line for the use of palivizumab recommends that it should be restricted for use in the first 6 months of life in highrisk children, defined as premature infants. [21, 22] Furthermore, infants with chronic lung disease of prematurity or those with congenital heart defects with signi ficant haemodynamic instability (complex lesions with pulmonary hypertension) and the premature neonate who is a graduate of an ICU and has ongoing respiratory or cardiac compromise (diuretic, oxygen or corticosteroid dependent), should be covered during the first 24 months of life and during the RSV season. RSV prophylaxis may be considered in children with profound immunocompromise or pulmonary neuro muscular disease. The value of palivizumab is uncertain in children with Down syn drome, cystic fibrosis, recurrent wheeze and in nosocomial outbreaks.
It would be appropriate to use palivizumab between January and May in high-risk infants (<6 months old), as the RSV season in SA is between February and June. [25] The standard dose of 15 mg/kg given monthly for 5 months is advocated. All risk groups who are resident in hospital and for whom palivizumab is indicated, should be initiated on palivizumab in hospital as per guidelines, and not only after they are discharged.
Indications for palivizumab
Indications for palivizumab are the following: • Premature infants of gestational age of <36 weeks at birth and <6 months of age at the start of the RSV season (February). Prophylaxis should be continued until the end of the RSV season (last dose in May).
• Children of any gestation and <24 months of age at the start of the RSV season, with any of the following: chronic lung disease of prematurity, chronic lung disease, primary immunodeficiency, haemodynamically significant congenital heart disease.
• High-risk premature infants should commence their prophylaxis while still in hospital.
RSV vaccine
While RSV vaccine development was stalled for many years owing to the adverse effects associated with a formalin-inactivated vaccine, substantial progress has recently been made in the development of a possible vaccine. [26] There are several candidate vaccines undergoing Phase 1 trials and two undergoing Phase 2 studies (a live attenuated vaccine for immunisation of infants and an F-protein vaccine for immunisation of pregnant women as a strategy to protect infants). A Phase 3 study, using a novel strategy of immunisation of pregnant women in their last trimester of pregnancy, has begun. This strategy will potentially be effective to prevent disease in young infants by transplacental antibody transfer and prevention of infection in mothers. Such a strategy may have to be coupled with vaccination of infants to enable more protection of young children for the first two years of life.
Parent and caregiver education
Management of children with bronchiolitis requires that parents or caregivers be educated about the condition. This is critical when children are not admitted to hospital, but also after discharge. The key elements of an educational message are listed in Table 2 . 
